Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: B/F/TAF; BIC/FTC/TAF; Bictegravir/F/TAF; Bictegravir/tenofovir-alafenamide/emtricitabine; Biktarvy; Emtricitabine/bictegravir/tenfovir-alafenamide; Emtricitabine/GS 9883/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/GS-9883; Emtricitabine/tenofovir-alafenamine/bictegravir; F/GS 9883/TAF; GS 9883/F/TAF; GS 9883/tenofovir alafenamide/emtricitabine; GS-9883/emtricitabine/tenofovir alafenamide; J05AR20; Tenofovir-alafenamide/bictegravir/emtricitabine; Tenofovir-alafenamide/emtricitabine/bictegravir; Tenofovir-alafenamide/emtricitabine/GS-9883; Tenofovir-alafenamide/GS-9338/emtricitabine

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Oxazepines; Purines; Pyrazines; Pyridones; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase I inhibitors; DNA polymerase II inhibitors; HIV integrase inhibitors; HIV reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 06 Nov 2019 Safety and efficacy data from the phase III (Study 1489 and Study 1490) in HIV-1 infections released by Gilead
  • 16 Aug 2019 Launched for HIV-1 infections (Treatment-experienced) in Canada (PO), prior to August 2019
  • 16 Aug 2019 Launched for HIV-1 infections (Treatment-naive) in Canada (PO), prior to August 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top